Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | RECQL | P46063 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 5/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23052431 | 0.99 | SMN1; SMN2 (0.65) | SMN1; SMN2KDM4ERECQLALDH1A1CYP3A4 | |
| SCHEMBL12169393 | 0.85 | SMN1; SMN2 (0.71) | SMN1; SMN2KDM4ERECQLALDH1A1CYP3A4 | |
| SCHEMBL12169367 | 0.83 | SMN1; SMN2 (0.73) | SMN1; SMN2KDM4ERECQLALDH1A1CYP3A4 | |
| SCHEMBL23052524 | 0.81 | KMT2A (0.58) | SMN1; SMN2ALDH1A1TSHRLMNAHTT | |
| SCHEMBL12169400 | 0.80 | SMN1; SMN2 (0.68) | SMN1; SMN2KDM4ERECQLALDH1A1CYP3A4 | |
| SCHEMBL12572276 | 0.79 | SMN1; SMN2 (0.71) | SMN1; SMN2KDM4ERECQLALDH1A1CYP3A4 | |
| SCHEMBL12188930 | 0.79 | SMN1; SMN2 (0.71) | SMN1; SMN2KDM4ERECQLALDH1A1CYP3A4 | |
| SCHEMBL12315297 | 0.78 | SMN1; SMN2 (0.65) | SMN1; SMN2KDM4ERECQLALDH1A1CYP3A4 | |
| SCHEMBL12189228 | 0.77 | SMN1; SMN2 (0.73) | SMN1; SMN2KDM4ERECQLALDH1A1CYP3A4 | |
| SCHEMBL9906394 | 0.77 | KMT2A (0.66) | SMN1; SMN2KDM4ERECQLALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210834-A1 | RNA METHYLTRANSFERASE INHIBITOR, SCREENING METHOD THEREFOR, ANTI-CANCER AGENT EFFICACY ASSESSMENT MARKER, AND KIT FOR EFFECTIVELY PREDICTING FTSJ1 INHIBITOR | NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY (JP) | 2023-07-06 | — | — | US | disclosed |
| WO-2021039824-A1 | RNA METHYLTRANSFERASE INHIBITOR, SCREENING METHOD THEREFOR, ANTI-CANCER AGENT EFFICACY ASSESSMENT MARKER, AND KIT FOR EFFECTIVELY PREDICTING FTSJ1 INHIBITOR | 国立大学法人 岡山大学 | 2021-03-04 | — | — | WO | disclosed |
| WO-2021039824-A1 | RNA METHYLTRANSFERASE INHIBITOR, SCREENING METHOD THEREFOR, ANTI-CANCER AGENT EFFICACY ASSESSMENT MARKER, AND KIT FOR EFFECTIVELY PREDICTING FTSJ1 INHIBITOR | 国立大学法人 岡山大学 | 2021-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210834-A1 | RNA METHYLTRANSFERASE INHIBITOR, SCREENING METHOD THEREFOR, ANTI-CANCER AGENT EFFICACY ASSESSMENT MARKER, AND KIT FOR EFFECTIVELY PREDICTING FTSJ1 INHIBITOR | EMG1, TRDMT1, BCDIN3D | SMN1; SMN2 3452/4885KDM4E 1740/4885RECQL 1362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.